Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Change in Account Payables (2024 - 2025)

Avidity Biosciences (RNA) has disclosed Change in Account Payables for 2 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables rose 236.72% year-over-year to $2.7 million, compared with a TTM value of $8.0 million through Dec 2025, changed N/A, and an annual FY2025 reading of $3.8 million, up 1188.54% over the prior year.
  • Change in Account Payables was $2.7 million for Q4 2025 at Avidity Biosciences, down from $5.8 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $5.8 million in Q3 2025 and bottomed at -$1.2 million in Q3 2024.